ArticlePolymers2025
Brewers' Spent Grain-Derived Arabinoxylan as a Sustainable Filler for Enhanced PHBV Biocomposites.
Article in Polymers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV) is a highly promising biodegradable and bio-based thermoplastic recognized for its environmental benefits and potential versatility. However, its industrial adoption has been limited due to its inherent brittleness and suboptimal processability. Despite these challenges, PHBV's performance can be tailored for a wide range of applications through strategic modifications, particularly by blending it with other biodegradable polymers or reinforcing it with natural fibers and bio-based fillers. This study explores the potential of brewers' spent grain (BSG) as a sustainable source for the development of PHBV biocomposites. The biocomposites were synthesized by incorporating arabinoxylan-bound benzoate, which can be derived from BSG, as a sustainable filler at concentrations of 4% and 10%
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.